Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) gained 24.15 Percent and closed its previous trading session at $3.29. The stock traded with the average Volume of 3.66 Million at the end of last session.
The company reported its last earnings Actual EPS of $-0.22/share. While, the analyst predicted that the company could provide an EPS of $-0.17/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.05/share which shows an Earnings Surprise of -29.4 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 28.27% where SMA50 and SMA200 are 86.93% and 169.55% respectively.
The company shows its Return on Assets (ROA) value of -34%. The Return on Equity (ROE) value stands at -123.6%. While it’s Return on Investment (ROI) value is -162.5%.
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) currently has a Weekly Volatility of 13.01% percent while its Monthly Volatility is at 14.18% percent. While talking about Performance of the Stock, Eleven Biotherapeutics, Inc. currently has a Weekly performance of 16.25%, monthly performance percentage is 119.33 percent, Quarterly performance is 265.56 percent, 6 months performance shows a percent value of 383.82% and Yearly Performance is 100.61 percent.
Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.